Holistic Practitioners Gain Deeper Insight into Palmitoylethanolamide (PEA) for Pain and Inflammation Management
Friday, 10 July 2026 18:42 By Erik Goldman
Pain and chronic inflammation represent pervasive challenges for holistic practitioners, impacting a broad spectrum of conditions ranging from degenerative joint diseases and neuropathies to migraines, menstrual disorders, and the recovery process following strenuous physical activity. The current pharmaceutical landscape, while offering interventions, often encounters limitations characterized by adverse side effects, the potential for dependency, and an inability to fully address the intricate underlying biological mechanisms of neuroinflammation.
In response to these persistent clinical needs, a comprehensive webinar was recently held, delving into the therapeutic potential of palmitoylethanolamide (PEA). This naturally occurring lipid mediator, endogenously produced by the human body, plays a crucial role in regulating pain perception and facilitating the repair of damaged tissues. The session specifically highlighted Levagen®+, Saanroo’s clinically validated PEA formulation, which leverages patented LipiSperse® dispersion technology. This advanced delivery system is designed to significantly enhance the absorption and bioavailability of PEA, thereby optimizing its therapeutic efficacy.
The Scientific Foundation of PEA’s Efficacy
The webinar featured chemist Ramasamy V. Venkatesh, a distinguished figure with over four decades of experience in the pharmaceutical and nutraceutical industries. Venkatesh provided a thorough scientific exposition on the clinical application of PEA, meticulously outlining its multi-receptor mechanism of action. He explained how PEA primarily exerts its effects through the activation of PPAR-α (Peroxisome proliferator-activated receptor alpha). Furthermore, he elaborated on PEA’s indirect modulation of the cannabinoid receptors CB1 and CB2, as well as its interactions with other key receptors such as GPR55 and TRPV1.
Venkatesh emphasized the concept of PEA as a "parallel endocannabinoid" signaling pathway. This distinction is critical, as it allows PEA to address both peripheral and central pain signaling effectively without inducing the psychoactive effects commonly associated with other cannabinoid-related compounds. This unique characteristic positions PEA as a valuable tool for practitioners seeking to manage pain holistically and safely.
Clinical Evidence Supporting Levagen®+
A significant portion of the webinar was dedicated to a comprehensive review of the clinical research surrounding Levagen®+. Ramasamy V. Venkatesh presented findings from multiple randomized, double-blind, placebo-controlled trials that have investigated the efficacy of Levagen®+ across various pain and inflammation-related conditions. Key highlights from these studies included demonstrated effectiveness in alleviating joint pain and stiffness, providing relief from acute menstrual pain, reducing the frequency and intensity of migraines, and accelerating recovery from exercise-induced muscle damage.
The presentation underscored the importance of understanding how to integrate Levagen®+ into patient care plans for a diverse range of individuals. Rather than promoting it as a universal panacea, Venkatesh advocated for its application as a precision therapeutic agent. This approach emphasizes targeting the endocannabinoid-adjacent pathways that are intrinsically involved in the complex physiological processes of pain perception and inflammatory response.
Background and Context of the Webinar
The webinar, hosted by Saanroo, a prominent entity in the nutraceutical sector, was part of an ongoing effort to educate healthcare professionals on emerging and scientifically validated ingredients. The date of the webinar, July 10, 2026, falls within a period where there is a growing global demand for natural and effective pain management solutions that offer alternatives to conventional pharmaceuticals.
The choice of Saanroo as the sponsor is significant. The company is known for its commitment to innovation and the development of branded ingredients supported by robust scientific evidence. Their proprietary LipiSperse® technology, which enhances the solubility and absorption of lipophilic compounds like PEA, represents a crucial advancement in making such natural compounds more bioavailable and therapeutically effective. This technological edge addresses a common limitation in the delivery of many natural compounds, positioning Levagen®+ as a leader in its category.
The format of the webinar, featuring a leading chemist and presenting clinical data, reflects a growing trend in the nutraceutical industry towards greater scientific rigor and evidence-based marketing. This approach aims to build trust and credibility among healthcare providers who are increasingly seeking to incorporate evidence-backed natural therapies into their practices.
Ramasamy V. Venkatesh: A Leading Expert in the Field
Ramasamy V. Venkatesh’s extensive background lends significant weight to the insights shared during the webinar. His four decades of experience in the healthcare industry, encompassing both pharmaceuticals and nutraceuticals, provide him with a unique and comprehensive perspective. As the founder and managing director of the Gencor Group worldwide, he has been instrumental in navigating the complexities of international business in these sectors, conducting operations in over 70 countries.
His expertise spans the entire product lifecycle, from research and development management and scientific reviews to product development, clinical trial oversight, branding, and the formation of strategic partnerships. Venkatesh has a proven track record of successfully launching branded products globally within the nutraceutical market. His contributions have been recognized with accolades such as the Nutri Champion Award from NutraIngredients in 2024, acknowledging the substantial impact of his work on the dietary supplement industry. He is widely respected for his dedication to elevating industry standards through the use of high-quality, clinically supported ingredients.
Beyond his professional accomplishments, Venkatesh is also recognized for his strong work ethic and his commitment to promoting equal opportunities and empowering women in business and sports. This broader perspective further enriches his contributions to the field, suggesting a holistic approach that extends beyond mere scientific innovation.
Supporting Data and Clinical Implications
The clinical data presented on Levagen®+ offers compelling evidence for its utility. For instance, studies on joint pain have shown significant reductions in discomfort and improvements in mobility. In the context of menstrual pain, clinical trials have indicated that Levagen®+ can offer a comparable or superior effect to some over-the-counter pain relievers, with a potentially better safety profile. Migraine sufferers have also reported a decrease in the frequency and severity of their headaches. The application in sports recovery highlights PEA’s role in mitigating muscle soreness and inflammation, thereby shortening downtime for athletes.
The implications of these findings are substantial for holistic practitioners. They suggest that PEA, particularly in its bioavailable form as Levagen®+, can be a valuable adjunctive therapy for a wide array of chronic pain and inflammatory conditions. This offers a pathway to address patient needs that may not be fully met by conventional treatments, potentially reducing reliance on pharmaceuticals with known side effects.
The Role of LipiSperse® Technology
A critical component of Levagen®+’s efficacy, as emphasized by Venkatesh, is the patented LipiSperse® dispersion technology. PEA is a lipophilic molecule, meaning it is fat-soluble. This characteristic can pose challenges for absorption in the aqueous environment of the gastrointestinal tract. LipiSperse® is a hydrophilic matrix that encapsulates the PEA, effectively improving its dispersion and solubility in water. This technological innovation leads to enhanced dissolution rates and increased bioavailability, ensuring that a greater proportion of the ingested PEA is absorbed into the bloodstream and available to exert its therapeutic effects. Without such advanced delivery systems, the clinical benefits of PEA might be significantly diminished due to poor absorption. This underscores Saanroo’s commitment to science-driven product development.
Broader Impact and Future Directions
The increased understanding and application of PEA, as facilitated by events like this webinar, have broader implications for the future of pain and inflammation management. It signals a growing acceptance and integration of scientifically validated natural compounds into mainstream healthcare. For holistic practitioners, this translates into a more robust and evidence-based toolkit.
The focus on PEA’s endogenous nature and its "parallel endocannabinoid" pathway also aligns with a growing interest in understanding and supporting the body’s intrinsic regulatory systems. As research into the endocannabinoid system and related pathways continues to expand, compounds like PEA are likely to play an increasingly central role.
The success of Levagen®+ could also spur further research and development into other naturally occurring compounds with similar mechanisms of action. The emphasis on bioavailability and clinically validated formulations is likely to become a benchmark for future product development in the nutraceutical industry. This trend benefits consumers by ensuring they have access to more effective and reliable natural health products.
The proactive approach taken by Saanroo in sponsoring such educational initiatives demonstrates a commitment to not only marketing products but also to advancing the scientific understanding and clinical application of their ingredients. This dedication to education is crucial for bridging the gap between scientific discovery and practical patient care, ultimately contributing to improved health outcomes for individuals suffering from chronic pain and inflammation. The continued exploration of compounds like PEA offers a promising avenue for developing safer, more effective, and more holistic approaches to healthcare.
